Krystal Biotech (KRYS) Interest & Investment Income (2017 - 2026)

Krystal Biotech has reported Interest & Investment Income for 9 years, with the latest figure at -$1.2 million in Q2 2026.

• Interest & Investment Income for Q2 2026 came in at -$1.2 million, down 667.72% year-over-year; the trailing twelve-month figure through Jun 2026 was -$2.3 million (down 367.35% YoY), and the FY2025 annual result was $642000.0, up 245.91% from the prior year.
• Interest & Investment Income rose to -$1.2 million in Q2 2026, from -$1.6 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $1.8 million in Q3 2024 and troughed at -$1.6 million in Q1 2026.
• A 5-year average of -$95611.1 and a median of -$152000.0 in 2023 frame the typical range for Interest & Investment Income.
• The widest annual swing landed in 2022, when Interest & Investment Income slumped 34366.67%; it then surged 1360.27% in 2024.
• A 5-year view of Interest & Investment Income shows it stood at $747000.0 in 2022, then jumped by 45.38% to $1.1 million in 2023, then sank by 206.17% to -$1.2 million in 2024, then surged by 82.57% to -$201000.0 in 2025, then slumped by 503.48% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were -$1.2 million in Q2 2026, -$1.6 million in Q1 2026, and -$201000.0 in Q4 2025.